In vivo studies showed that CxcR2 signaling significantly contributed to enhanced metastasisobserved from the TGF-β1 signaling deficient mammary carcinoma cell population, when compared with the control mammary carcinoma cells [98]. This evidence concerns the gene CXCR2 and breast carcinoma.